Healthcare Startups funded by Y Combinator (YC) 2024

Ginkgo Bioworks is the organism company. We design custom organisms for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

We make oral drugs to treat and prevent viral infections - like COVID-19.

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

Clipboard Health exists to lift as many people up the socioeconomic ladder as possible. We dramatically improve lives by letting healthcare professionals turn extra time and ambition into career growth and financial opportunity. We achieve this with our app-based marketplace that connects healthcare facilities and healthcare professionals, allowing healthcare professionals to book on-demand shifts and healthcare facilities to access on-demand talent. Our mission is to enable healthcare professionals to work when and where they want and to enable healthcare facilities to meet their talent needs. Clipboard Health is a fast-growing Series C startup with classic two-sided network effects. We have product-market fit, generate substantial revenue, and we are helping nurses fix healthcare one shift at a time. Clipboard Health is a diverse and inclusive company with a global, remote-first team of hundreds of people. We’ve been featured on YC’s Top Companies and grown our revenue 25x in the last 18 months. We need your help to keep growing so we can serve more healthcare professionals, healthcare facilities, and patients.

Nurx is a telemedicine startup focused on increasing access to healthcare, starting with birth control and PrEP services.

We're a women’s health company making personalized reproductive health information more accessible, earlier in life. We make the same laboratory tests that were previously confined to fertility clinics more accessible for women at home. By arming women with powerful information about their reproductive health, Modern Fertility is closing the fertility information gap and enabling women to own the decisions impacting their bodies and futures. We've raised $22 million from Forerunner Ventures, Maveron, Union Square Ventures, First Round Capital, #Angels and Y Combinator.

DrChrono develops the essential platform and services for modern medical practices to make care more informed, more interactive, and more personalized. The open platform powers telehealth, electronic health record (EHR), practice management, medical billing, and revenue cycle solutions for physicians and patients, and is fully extensible via a robust API and marketplace of applications and services. The platform is used by thousands of physicians and millions of patients, and is facilitating millions of patient appointments and is processing billions of dollars in medical billing. For more information about DrChrono, visit www.drchrono.com

Sanvivo builds a multisided platform to enable customers to order medications, get pharmaceutical advice, and book health services at local pharmacies in Europe. Just like Shopify for pharmacies. Sanvivo gives pharmacies software to take, fill and schedule delivery for online orders. We also bring instant demand through integrations with 3rd party consumer delivery companies. Almost all pharmacies in Europe are, by law, local 1-person businesses. And they are not ready for online orders. Regulatory changes require pharmacies to take and fill e-prescriptions (roll-out Jan-23), but many have no way to do this online today. Sanvivo uses technology to give local pharmacies digital superpowers, enabling them to combine fast supply and high-quality consultation with state of the are e-commerce solutions.

We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.

Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.

We are India's fastest medicine delivery service. We deliver medicines in just 30 minutes. We have built highly optimized pharmacy stores and a set of internal tools designed to process prescriptions quickly. We also provide easy-to-integrate APIs and SDK for anyone to start a virtual pharmacy without needing a license, pharmacy, or delivery fleet. Any doctor, teleconsultation app, or EMR provider can start delivering medicines to their patients on WhatsApp or App using our service in the background. We have more than 80 B2B partners, including India's top teleconsultation apps, EMR providers, hospitals, elderly care apps, and insurance providers. We operate 24/7 in Gurgaon, New Delhi, and Moradabad and deliver over 15,000 orders monthly. So far, we have processed more than 250K orders and done thousands of life-saving deliveries. We started in 2020 with the vision to build a centralized health record system for India. We had an AI-powered EMR app for doctors and a SaaS for diagnostic labs to add patients' medical records to Farmako Health ID. We have more than 3M health records added on Farmako. In 2022, the Indian government launched ABHA Health ID and we became one of the first official partners with them. In 2023, we launched quick medicine delivery and decided to move forward with ABHA Health ID for medical records. Now, we are building a safe health assistant inside our medicine delivery app, which will be connected to your Health ID and all your past medical records. Our goal is to make it a super-safe and accurate health assistant for the world, which can eliminate your doctor in the long run for all primary care issues.

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.

Rebuilding Africa's health system, with focus on prevention this time

We empower people to a lasting, healthier lifestyle through wellness programs and personalized support.

Velorum Therapeutics is developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism. We have shown our drugs work in mice and plan to begin human clinical trials next year, starting with the #1 cancer killer – lung cancer.

We’re building technology to finance universal healthcare by crowdfunding surgeries and providing coverage for primary care.

Attunement is the first remote monitoring platform that specializes in behavioral health. We provide multimodal assessments and treatment recommendations to help with the mental health crisis experienced by 57.8 million Americans.

We have developed an AI platform enabling to accelerate the discovery and the design of genomic therapies such as Cell Therapies, RNA Therapies and DNA Therapies.

Over 80% of maternal mortalities were preventable with earlier intervention. Currently, doctors miss >50% of moms who have life-threatening complications and wait until labor to start doing manual risk assessments, at which point it's too late. Elythea's proprietary ML models catch life-threatening obstetric complications (like postpartum hemorrhage, preeclampsia/eclampsia, emergency c-section, preterm labor, and more) as soon as the first visit. We automatically analyze relevant demographic and clinical risk factors, flag high-risk patients, and provide evidence-based interventions, giving doctors months in advance to intervene and prevent complications from ever happening. Our global clinical studies have shown that we can catch 2-3x more complications than clinical judgment 10x sooner.

Relay is an app that helps people overcome addiction through peer support and accountability – starting with pornography addiction. It’s like if Alcoholics Anonymous were invented in 2024. For example, when someone is struggling in isolation, Relay matches them with 3-7 other peers with the same challenge, makes it easy to reach out for help when vulnerable, and enables change through shame-free accountability and facilitated connection.

Healthcare is delivered by teams – nurses, doctors, and staff, specific to each hospital, clinic, and department. They want to do their best, but cannot keep up with constantly changing information. Burnout >50%. Unprecedented turnover. Growing medical errors (the #3 cause of death in the US). $100B+ in waste. Elemeno Health is a UCSF and Y Combinator-backed B2B SaaS for healthcare facilities– “a playbook in your pocket,” customized to support frontline teams with bite-sized training and communication at their fingertips, accessible 24/7 on any device. Our efficacy is demonstrated in our published results, passionate clients, and consistent renewals. 20x ROI. 75% decrease in medical errors.

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need. We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.

Pre-clinical results published in the Journal of Neuro-Interventional Surgery. Technology presented at the World Live Neurovascular Conference. Technology selected as a top 3 finalist for Innovator of the Year by the Congress of Neurological Surgeons. Raised a Series A to fund commercialization (FDA Clearance, Health Canada, ISO 13485, First-in-man and early revenue).

We provides tools, data and systems to facilitate real-time insights, decluttering outbreak detection and enhancing risk mitigation. Our surveillance is used by industry, public heath and consumers globally.

Chronic pelvic pain is a debilitating condition, that impacts over 15 million US women and costs over $39 Billion each year to manage. V-Flow medical has developed a trio of products that target the root cause of chronic pelvic pain, allowing millions of women to avoid opioid use and restart living a normal, pain free life. The V-Flow team has successfully scaled, multiple start-up medical device companies in various clinical disciplines with a combined exit value of over $4B. We have developed a broad IP portfolio covering both device design and method of application. A recent landscaping identified no competing IP for our indication of use. We have tested our beta prototypes and are initiating animal models ahead of a planned first in human investigation in Q1 2023. Following discussion with the NIH program advisors, we have been encouraged to apply for a phase 1 grant, call to action for the Heal initiative to find new diagnostic and non-drug treatments for chronic pelvic pain.

As healthcare costs have increased, the patient's home has become incredibly important as a site of care. Yet, patients recovering at home are highly underserved. Patients can only get better at home if they receive the high-quality care that they need reliably. The existing in-home care process involves patchwork of different vendors, all connected through faxes by nurses. We're building modern, robust software that solves this challenge and brings this market online.

Science Exchange powers R&D outsourcing for the world’s top life sciences companies. Our marketplace gives scientists access to the innovation and research they need and our platform fully automates R&D outsourcing from source to pay so scientists can focus on what they love—science.

Medmonk is a technology platform that helps fight non-adherence. It enables pharmacists to provide financial assistance to patients who are unable to pay for their medications. We partner with pharmaceutical companies, pharmacies, physicians, and health plans to improve outcomes by promoting access to chronic therapy. Medmonk is based on the premise that it's in everyone's best interest for medications to be used regardless of price. Patients get the care they need, insurers are protected against larger claims, and pharmaceutical companies and pharmacies get maximum use of their medications.

Qvin is the first and only healthcare service to scientifically prove menstrual blood can test for critical health information – just like a traditional laboratory blood test. Women's health has always been under-prioritized in science. We still operate in a world built by men, for men. It’s why in 2014, Dr. Sara Naseri and Søren Therkelsen started Qvin to research, develop, and patent a product that powers an underserved and understudied population—women. Over 70% of the decisions our doctors make are influenced by blood test results. Every month, 1.8 billion people across the world menstruate. However, the blood our bodies naturally deliver every month has never been explored as a testing source. And yet, menstrual blood has been left unexplored. Qvin is the first and only healthcare service to use period blood as a non-invasive blood test. We exist to give women an easy, insightful way to monitor existing health issues, proactively screen for others, and go into doctor visits more informed and confident of their own health. Our health technology platform helps women manage their health better through a non-invasive blood collection device named the Q-Pad™. All of us at Qvin want to move the study of women forward. We want to close the gender data gap. And we stand for every person who identifies with women, however they define it.

X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc

We are a service for people to learn about their personal environmental exposures. Our first product is a urine test for exposure to chemicals in everyday products.

It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.

Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.

Dear Brightly offers prescription skin products online. Our mission is to get people access to the most effective, dermatologist vetted skincare products for healthy skin, using technology.

We believe that no emergency should have to wait. To make this a reality we build AI that instantly reads medical scans and enables critical care teams to make diagnoses better than radiologists. This saves lives by getting emergencies to treatment immediately and by discharging non-emergent patients quickly so the next emergency doesn’t have to wait either.

Flowly’s mobile app is the VR version of Calm with a focus on reducing chronic pain for 100 million Americans. Flowly subscribers receive a $5 VR headset and Heart Rate sensor that collects a user's biometric data like HR and HRV, and converts it to visualizations in virtual experiences that reduce pain by 46%. Flowly is backed by the National Institutes of Health.

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics. The Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself. Our Solution: Digistain addresses this critical gap. Our technology transforms the current diagnostic process by enabling hospitals to analyze patient samples in-house using existing equipment, supplemented with our innovative technology. This approach offers near-instantaneous decision-making data, a stark contrast to the existing month-long waits. Central to our technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumour in the infrared spectrum, providing a personalized risk score. This score guides oncologists in selecting the most effective, individualized treatment plans, potentially reducing unnecessary chemotherapy and its harmful side effects. Impact and Potential: Our solution not only challenges the status quo in technology but also in accessibility. In a landmark government-commissioned study, Digistain demonstrated clinical evidence on par with the market leader, but at a fraction of the cost and time. Already making waves in clinical practice globally, with insurance reimbursement at leading cancer centers, our technology represents a paradigm shift in cancer care. Recognized by the Institute of Physics, the Royal Society, and Imperial College for our innovative contributions, and supported by entities like the NHS, Y Combinator, and the European Investment Bank, Digistain is more than a company—it’s a movement towards equitable, effective cancer treatment. With the potential to democratize access to life-saving diagnostics, Digistain is not just envisioning a better future for cancer patients; we are actively creating it.

Reliance Health uses technology to make quality healthcare delightful, affordable and accessible in emerging markets. Through an integrated approach that includes affordable health insurance, telemedicine and a combination of partner and proprietary healthcare facilities, Reliance Health offers innovative healthcare solutions that meet the needs of emerging markets including Nigeria, Egypt and growing

Makani Science is a medical device company based in Irvine, California. We have created the world's first wireless patch that can accurately and continuously monitor breathing. The company is co-founded by Dr. Michelle Khine and Dr. Michael Chu, two experts in the wearable monitoring space from the University of California, Irvine. The Makani Science system will collect unique breathing waveforms from patients in everyday environments to create the first large database of respiratory patterns associated with different diseases. Data will be collected through systems sold to our initial beachhead market, where we will help improve monitoring safety in patients being sedated for medical procedures. Our long-term goal is to combine machine learning with this database to identify and predict respiratory complications for different patient populations. We have a highly experienced team and will be FDA cleared in our beachhead market within a year.

Codes automates patient record collection for providers. Today, documents are scattered across EHRs, other doctors, and faxes; we use AI to compile & analyze docs before the first appointment.

We help hospitals 🏥 hire nurses 🧑🏻‍⚕️ from all around the world 🌏 and with technology make the complexity of immigration and licensing simple.

Current Description: RTHM provides virtual-first care for complex illness including Long COVID, ME/CFS, POTS, and mast cell activation. Many clinics focus on teaching patients how to better cope with symptoms, which is helpful, but we don’t stop there. We develop collaborations & partnerships so our patients access to the most promising testing and root-cause directed early therapies for their illness(es) with the goal of simplifying and streamlining the most efficient and effective clinical pathways so they can be scaled in the form of low cost online modules overseen remotely by clinicians. In conjunction with clinical care, RTHM operates a clinical lab and collects deep molecular data with robust clinical context to develop AI-powered diagnostics and better ways of predicting which treatments may work best for whom.

Diffuse is building generative AI for protein design. Our mission is to build AI systems that engineer new and useful proteins with unprecedented control and accuracy. Our team has been behind breakthroughs in AI protein design for the past 7 years, including the first experimental validation of AI-generated proteins and diffusion models for protein structure and sequence.

Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.

Vena Vitals makes a small sticker that monitors blood pressure continuously. We've shown that it works in the operating room and is as accurate as the best tools doctors have today, at a fraction of the cost. We're a team of health tech scientists with multiple past startups and exits, and we've built products that have scaled to over 2M users.

We make devices that help cancer patients prevent the side effects of cancer treatment, including hair loss, neuropathy and infertility. Our first product, Lily, is a wearable cap that enables chemotherapy patients to prevent hair loss in a comfortable, portable way, while our second product, Lilac, is the world's first device to prevent the peripheral nerve damage caused by cancer treatment.

Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.

Pipe|bio is the bioinformatics cloud for antibody / peptide screening & drug development. We enable scientists to analyze and manage massive amounts of DNA sequencing data themselves without the need for bioinformaticians or programmers. The software is highly visual and enables you to overlay and filter information from different sources across your organization; be it assay data, sequence data or other process metadata. Insights from past results can be used to guide new experiments and they get better as you upload more and more data. Team leads get oversight and these capabilities combined empower organizations to find better drugs, faster. We believe that science moves faster when scientists can curate and analyse their own data.

We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.

Daybreak offers comprehensive and clinically-validated online mental health services designed for youth, like teletherapy, psychiatry and digital education. We partner with schools and pediatric groups to make access to services easy, and strive to deliver zero cost to the end consumer through insurance and government funding.

BrainHi is an automated receptionist for local businesses. Local businesses are in search of new clients and revenue, yet 25% of phone calls to local businesses are missed and 80% of potential clients don’t leave voicemails. BrainHi uses AI to create an automated receptionist that answers missed calls 24/7 and chats with clients to schedule appointments and answer admin questions, resulting in more business. Cofounders Emmanuel and Israel started BrainHi after Hurricane Maria made communicating with doctors offices nearly impossible on the island of Puerto Rico.

Rinse is building the One Medical for dental. Beautiful studios, easy to book same day appointments, and anxiety-free care focused on prevention, not the upsell.

Bemlo empowers healthcare organizations to offer their employees the flexibility they require. Did you know that the US will be 4 million healthcare workers short by 2026? Post-COVID, a record number of professionals have left the industry due to burnout and 3/10 are considering leaving. We increase retention by making it possible for nurses and doctors to work on their terms - without having to go through staffing agencies. Our customers post vacant shifts to their own pools as well as our marketplace of vetted professionals increasing fill rates while keeping expenses manageable. We serve healthcare organizations from single private elder care homes to large public regional healthcare systems with multiple hospitals and thousands of staff.

We empower mental healthcare clients with virtual reality sessions that are additive to traditional therapy. Clients regain their self-reliance the moment they are given the chance to contribute to their treatment. Therapists can focus on the aspects of treatment that e-health is not equiped to deal with. Treatment efficiency goes up - costs go down: E-health the way it was meant to be.

Correlia Biosystems is a UC Berkeley spinoff company based in Berkeley, CA. Correlia develops innovative microscale tools that accelerate rapid quantification of biomolecules. Our versatile "SimpleScan" technology opens up new biological questions from one microliter of sample, with rapid results that allow for dynamic monitoring of protein expression profiles (rather than simple end-point measurement). Applications range from enabling next-gen proteomic data sets to point-of-care diagnostics.

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

Equipt Health makes it easy for any healthcare company to offer prescription medical devices to patients. We handle the whole process: the packaging, the logistics, the clinical (via our provider network) and technical support, and the return of data from connected devices. We're starting with the diagnosis and treatment of sleep apnea at heliosleep.com.

In a nutshell: many diseases are caused by how much your cells squeeze (asthma, fibrosis, others). We discover drugs that control how much cells squeeze, with ease, to treat disease. We use patented bioMEMS technology to turn cell strength (cells' ability to pull/ squeeze) into a quantifiable metric in drug discovery, to help find better drugs for mechanical diseases. We screen 100,000s of drugs against numerous contractile human cell types to comprehensively map human mechanobiology (the "contractome") and identify promising drug development starting points to deliver novel medicines to treat mechanically-driven diseases including asthma, hypertension, preterm labor, fibrosis, and others.

Circle Medical is a venture-backed Y-Combinator healthcare startup on a mission to bring quality, delightful primary care to everyone on the planet. Built by top-tier physicians, engineers, and designers, our medical practice and underlying technology have pioneered how people find and receive care. Our focus on building directly for our patients and providers to address serious care accessibility issues has enabled us to grow over 3X year-over-year. We’re now using our most recent round of funding from WELL Health, backed by Sir Li Ka-shing, to continue building out our hybrid in-clinic and telemedicine model across all fifty states. As we enter the hypergrowth phase, we are looking for deeply motivated team players who are driven to solve some of the biggest challenges in healthcare so that people can live longer and healthier lives. More about us can be found on our website!

We make it easy for anyone in India to access healthcare over Zoom, Meet, or WhatsApp. We provide care in 11 local languages. For every appointment, we provide a concierge who manages all logistics for the patient & handles the back-office work for doctors. With this, we have cracked the code to make telehealth work in India.

Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button. By focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity. Rigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas. We've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.

Carrot is a simple and affordable way for companies of any size to build or enhance their fertility benefit. Carrot can help with egg freezing, infertility treatments including in vitro fertilization (IVF), LGBT+ conception, and more. Fertility care is daunting and scary; our focus is on improving the employee experience during high impact moments related to fertility-- helping save time, money and stress.

Our mission is simple: challenge archaic rules and implied medical conventions in healthcare to better serve patients and physicians. Gradia is the backbone of the entire patient experience, helping patients get personalized, high-touch care while also making clinics more money. With our software patients can stay informed/educated about the status of their care, easily communicate with their providers, and get direct access to a specialized virtual care team. Our software is currently at several clinics across the Southeastern US and helping thousands of patients get the care they deserve. 

We empower clinicians with our AI platform for developing differential diagnoses and drafting clinical plans.

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.

Digital Clinics are facing an existential problem - fix margins, or die. We’ve built a clinic, and seen the tech they need to fix their margins. Now we’re bringing this tech back to other clinics. For our first customer, we’re projected to generate $2.5M in revenue.

We use generative AI to call insurance on behalf of healthcare clinics. We save clinics up to 40 hours of calls every week over existing outsourced human solutions. Compared to the existing solutions for benefits verifications: - We're faster -- by default, we have a turnaround of 24 hours compared to typically a 3 day turnaround for competitors - We can reach more payors -- as long as they have a phone line, we can support calling them for benefits. There's quite a few payors in both medical and dental (e.g. Seledent) that have yet to offer a digital retrieval of benefits - We're reliable and consistent -- there is no person-to-person variation or question skipping when it comes to working with software

Helping pregnant parents save the most personal source of stem cells - from their umbilical cord and placenta - to unlock future disease treatments. Offering cord blood banking, cord tissue banking, and placenta stem cell banking.

Fitia is an automated meal planner and nutrition tracker for weight loss or muscle gain. Our users get personalized recipes based on their data and their local country ingredients, supported with an exclusive database of 1M foods & recipes.

We provide high quality data for AI radiology. We're building the biggest database of labeled medical data in the world, starting with radiology images. We sell to medical companies who are training and validating AI algorithms.

Malama enables HIPAA-compliant remote monitoring of diabetes in pregnancy, a condition that affects nearly 1 in 5 women. We will lower C-section and preterm birth rates by making it easy for patients and providers to track glucose and meal data. We launched in August 2022 and signed 5 pilot partners including Stanford Hospital and Santa Clara Valley Medical in two weeks, and have a pipeline of 30 more. Mika previously led clinical product innovation at UnitedHealthcare, the largest health insurance company in the world. Orlando, our technical cofounder, was a senior software engineer at AirBnb and Daniela, our creative cofounder, led brand strategy and design for L’Oreal. Malama is backed by the Stanford d.school, Y Combinator (S22), Alpine Investors and more.

Archform is teeth aligner software startup that lets orthodontists create, design and 3D print aligners within their own offices. The idea is to provide orthodontists with a way to better compete against some direct-to-consumer teeth aligner startups and cut down on the cost of Invisalign.

Reframe is the leading app to help people cut back on drinking. Reframe uses neuroscience & psychology to help people shift the way they think about drinking & help build great habits. We don't believe in stigma or restrictions. In the past 12 months, Reframe has had over 2M+ users and has helped more people cut back on alcohol use than any other org worldwide.

Wyndly (https://www.wyndly.com) fixes allergies by training patients' bodies to ignore their allergy triggers. Frustrated allergy suffers come to us when they no longer want to deal with pills and sprays. We diagnose the patient’s unique allergy profile and create a personalized treatment plan to give the patient lifelong allergy relief. Specifically, Wyndly is increasing access to sublingual immunotherapy (SLIT) for allergy care. For our patients, we're combining the convenience of telehealth and direct-to-consumer care with an exceptional patient experience that never loses the context of care. Wyndly represents an opportunity to change allergy care forever. With 60 million Americans suffering from allergies today, and with this number doubling over the coming years, there's simply an incredible need for the convenient care Wyndly provides. You can read more about us in [Techcrunch](https://techcrunch.com/2021/02/12/wyndly-aims-to-bring-allergy-drops-to-the-masses/). The Wyndly Model At Wyndly, we believe that better connections lead to better care, and we’re committed to making both happen at every step of the patient journey. Our allergy practice allows our patients to work with expert providers to develop personalized treatment plans for long-term allergy relief using clinically proven therapies. From a patient’s initial consultation to their final treatment delivery, we want the Wyndly experience to be a breath of fresh air for allergy sufferers – truly effective allergy relief, simply and efficiently delivered. Once we've conquered allergies, we're transforming the care model for every chronic condition. While transactional care for purchasing pills has flourished in telehealth, no one has gone after chronic care. Patients with chronic conditions are shuffled between providers, insurance, and more -- and they never feel heard. These patients deserve better, and we're going to give it to them. Wyndly is starting with allergies, but we'll expand into asthma, sleep apnea, and other conditions in the near future. Our values **Compassion**: We approach all our patients and partners with an open mind and a genuine desire to be of service. **Focus**: We do a few things very well, and are always clear about our boundaries and direction of travel. **Courage**: We embrace ambiguity and discomfort because we know that’s how we grow. **Progress**: We make something better every single day. *It boils down to empathy and forward momentum in everything we do.* The team Wyndly is proudly backed by Y Combinator and a leading group of angel investors and VCs. The founders are Dr. Manan Shah (Chief Medical Officer), an ear-nose-and-throat surgeon who’s a leading practitioner of telehealth in his specialty, and his cousin Aakash Shah (CEO), who led growth engineering at SparkGift (acquired by Stockpile in 2016) and Parse.ly (acquired by Automattic in 2021).

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.

Abalone Bio developed a technology to find antibody drugs that activate and modulate cell surface receptors, the “antennae” on cells that help convert chemical signals into cellular responses, like growth. Antibodies are a growing class of drugs that have tremendous safety and efficacy advantages over small molecules; 7 of the top 10 selling drugs are antibodies, earning an average of $7B in revenue. However, antibodies- especially ones that activate and modulate cell surface receptors- are hard to find. Abalone Bio expands the playing field for antibody therapeutics and enables us to previously access treatments for untreated diseases. We have already discovered a novel antibody that activates a non-opioid receptor that produces analgesia. We are developing this antibody into a treatment for neuropathic pain – a medical condition that currently is treated with drugs like addictive opiates. The same molecule is also a potential treatment for inflammatory and fibrotic diseases, all 1B+ markets.

MedPiper, a full-stack data platform that unifies and delivers end-to-end process for member and population health data: from data sourcing -> data verification -> data readiness -> data standardisation -> data logistics -> data interoperability . We have enabled payors, life sciences, pharma and health platforms obtain deeper insights into health, delivering better coverage and health outcomes. Aside from increasing network of healthcare & social determinant data partners, we move workloads that need extensive data handling workflows, to a simple workbench that can run and deploy rule engines on insights and braoder analytics : contributing to increased customer engagement, depeer personalised products, better GM structure etc for our clients. A few core things we deliver: - Easy integration (API-accessible), - A seamless experience (for all involved: patient, payor, provider, lab, mobile workforce), - A commitment to clinical quality standards,

Healthcare needs good data. At PicnicHealth, we are building deep real-world datasets fueling cutting-edge research while giving patients control of their own medical record data. These complete, clinically-rich datasets produce unique insights — across dozens of diseases — to ultimately get the right treatments into patients’ hands faster. We work directly with patients and leverage state of the art machine learning to transform messy medical records into structured, research-ready datasets. To date we’ve helped tens of thousands of patients securely access their records and proactively contribute to advancing research in diseases that impacts their lives.

Qventus’ mission is to simplify how healthcare operates so it just works — for everyone. The company offers an AI-based software platform that helps hospital teams make better operational decisions in real-time. Qventus addresses operational challenges across the hospital including emergency departments, perioperative areas, patient safety, in-patient, outpatient and pharmacy. Located in Silicon Valley, Qventus is honored to be working with leading public, academic and community hospitals across the United States. Founded in 2012, Qventus was named among Fast Company’s Most Innovative Companies for 2018. The company has also been recognized as a leader and innovator in operational excellence, with the 2016 Fierce Innovations Award in Healthcare and Healthcare Informatics 2017 Innovator Award. For more information about Qventus, please visit www.qventus.com

Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

Solugen is decarbonizing the chemistry of everyday life with enzymes and innovative metal catalysts. Our new to the world Bioforge platform technology can produce high value chemical goods that are biobased and carbon negative, at cost on par with current technologies. We are making sustainable chemistry accessible to all living things, to ensure a prosperous world exists for generations.

There are 10 million dialysis and bypass surgeries per year, but half of them fail. VenoStent saves lives with a wrap that goes around blood vessels during surgery so they don't fail.

We build AI models to create novel, high performing biomolecules faster. Our AI models simulate the biophysical properties of biomolecules and identify the most promising ones to be tested in the lab.

LEAH Labs is building a discovery engine for cell therapy development using virus-free gene editing technology, with dogs and cancer as a beachhead market. Dogs and humans get the same types of diseases, especially cancers, and are great models for one another. Our company is the first to bring CAR-T cell therapy to pets as both an unmet need for companion animal medicine, but also as a platform to discover and de-risk potential human assets. We operate under USDA jurisdiction, a regulatory environment prime for innovation that is orders of magnitude more cost effective to iterate within than FDA.

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

We combined microfluidic chip technology and a reagent cartridge to create the first personal DNA synthesizer. Until now most life scientists had to rely on out-sourced DNA synthesis, causing stagnating research. Kilobaser empowers every life scientist to synthesize DNA on their benchtop.

Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.

Intellect is a modern-day mental health company on a mission to make mental healthcare & wellbeing support accessible for everyone in Asia. Today, Intellect is the largest and fastest growing mental health tech company in Asia, serving over 2.5 million members and leading organisations globally through our mental health platform. Intellect was also selected as one of Google’s Best Apps of 2020. Intellect is backed by leading investors including Insignia Ventures Partners, Y Combinator, and an extensive list of family offices, big tech executives & renowned angel investors.

Almond is like One Medical but for women’s health: we make it easy to get great ObGyn care fast, both at our in-person offices and over telehealth. The problem with traditional ObGyn practices is that physician time is misused, so patients get slow care. We're rebuilding back-office tech that saves physicians time, and we're hiring a wider range of care providers roles, which let us deliver better outcomes to patients and reduce the amount of time it takes to get their issue resolved.